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Behavioural medicine: changing our behaviour
A growing body of evidence shows how to make behavioural interventions effective
Human behaviour is a major determinant ofhealth. Factors that influence health relatedbehaviours and people’s adaptive responses
to disease and illness are becoming better understood.
This understanding is leading to behaviourally based
interventions targeted at the level of the individual and
at service delivery, with impacts on both. Yet there is
much more to do. In the United Kingdom the Society
of Behavioural Medicine has been set up to promote
research into and the use of well founded behavioural
interventions.
An example of behavioural interventions working
at the individual level is that of psychological prepara-
tion of patients facing surgery: procedural information
and behavioural instructions reliably reduce the use of
analgesia and length of hospital stay.1 Similarly,
psychological treatments based on the principles of
cognitive behavioural therapy, when compared with
alternative active treatments, reduce the experience
and expression of chronic pain.2
Behavioural interventions can also trump prescrib-
ing in preventing disease: in a rare design comparing
behavioural interventions head to head with medica-
tion, intensive promotion of physical activity and
weight loss reduced the incidence of biochemical
diabetes in a high risk group by 58%,3 a greater reduc-
tion than that achieved by metformin.
Getting behavioural research into
practice
Behavioural interventions can also improve health-
care delivery. For example, organisational measures
such as changing a team’s skill mix and roles, or
reminder and prompt systems for clinicians, can result
in measured effects on clinicians’ behaviour and
clinically important reductions in blood pressure
among their hypertensive patients,4 again often greater
than those achieved in pharmacological trials.5
These are success stories. Yet such favourable
evidence is poorly or inconsistently translated into
clinical practice: patients are not routinely prepared for
clinical procedures; those with chronic pain are more
likely to be managed with medication than behavioural
interventions; and drugs are more likely than
systematic behavioural interventions to be deployed in
treating diabetes and hypertension.
As important as the success stories are the “work in
progress” stories. Thus in the area of adherence to
medication, systematic reviews of the many studies
available reveal little progress in developing interven-
tions that improve adherence rates, at least within ran-
domised trials.6 Most interventions to change profes-
sional behaviour such as clinical audit or educational
approaches have modest effects which vary unpredict-
ably with context.7 One major reason for this may be
that the interventions are designed with no basis in the
theory or evidence of why they might work.
The potential impact of behavioural interventions
in prevention and treatment raises the question as to
why they do not feature more strongly in research,
policy, and practice. One reason may be the lack of
skilled researchers and clinicians working to develop,
evaluate, and deliver these interventions, reflecting a
failure of investment. Systematic reviews repeatedly
highlight the problems of poorly developed and
described interventions, weak study designs, lack of
thought about context and target population, and
imprecise measures of behaviour.
The culture of medical practice itself may also be
antipathetic. Physicians remain the most powerful
voice in medicine. They are predominantly trained in
the use of drugs and surgery to control disease, rather
than behavioural interventions.
Furthermore, pressures on doctors from the phar-
maceutical and technology industries to deploy their
products are strong.8 Research funding from these
groups outstrips that from governments and charities
throughout the world. In 2003 the pharmaceutical
industry spent £3550m ($6250m; €5165m) on
research in the UK, more than twice the amount spent
by the Medical Research Council, Department of
Health, and major charities put together (Association
of the British Pharmaceutical Industry, personal
communication). The influence of the pharmaceutical
industry is important since, despite regulation, there is
evidence that its funding can lead to results biased in
favour of its products.9
The major imbalance between investments in
pharmaceutical development and in understanding
and supporting health related behaviours must be of
concern. While industry drives an important research
agenda it also strongly influences subsequent health-
care delivery. Yet the global health priorities of
preventing and managing chronic disease10 will clearly
not be achieved by prescription alone.
Changing researchers’ and practitioners’
behaviour
What is needed to increase the chances that effective
behavioural interventions are developed and incorpo-
rated into health care? Investment in more and better
quality research is essential, involving boundary break-
ing interdisciplinary collaborations.
Too much behavioural research is based neither on
valid theories of human behaviour nor on existing
empirical evidence. Interventions that are theory based
seem more effective in supporting behaviour change
than those that are not, and can be more effectively
generalised and disseminated.11 The proposed new
field of behavioural medicine within the Cochrane
Database proposes additional CONSORT items to be
reported in studies of behavioural interventions, detail-
ing their content and context to enable pooling of
homogeneous studies.
Behavioural medicine, as conceptualised in the
United States, brings together the many different disci-
plines and professions that aim to improve health and
healthcare outcomes through behavioural change. The
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field includes psychology, public health, geography,
sociology, health economics, architecture, epidemiol-
ogy, psychophysiology, sports medicine, and human
movement sciences as well as clinical medicine. The
UK’s new Society of Behavioural Medicine (http://
www.uksbm.org.uk) is one of 21 national societies
affiliated to the International Society of Behavioural
Medicine, an organisation aimed at achieving a better
understanding of the pathways between biological,
psychological, social, and cultural factors that influence
health as a basis for developing interventions that
improve health outcomes.
Progress in understanding and changing behav-
iour to improve health is modest but real. Potential
gains from the wider application of effective interven-
tions are large and include reduced costs for
healthcare systems and increased autonomy and
health for individuals. We need to challenge ambiva-
lent attitudes towards behavioural medicine among
those who develop science and health policy.
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